Table 1 Patients’ characteristics
| Â | All patients | PSA relapse | PSA persistence |
|---|---|---|---|
N | 129 | 62 | 67 |
Median age | 72 (47–83) | 74 (50–83) | 70 (47–83) |
Tumor stage | |||
 pT2 | 43 (33%) | 35 (57%) | 8 (12%) |
 pT3a | 36 (28%) | 17 (27%) | 19 (28%) |
 pT3b | 48 (37%) | 8 (13%) | 40 (60%) |
 pT4 | 2 (2%) | 2 (3%) | – |
Nodal stage | |||
 pN0 | 79 (61%) | 46 (74%) | 33 (49%) |
 pN1 | 37 (29%) | 8 (13%) | 29 (43%) |
 pNx/cN0 | 13 (10%) | 8 (13%) | 5 (8%) |
Positive surgical margins | 60 (47%) | 16 (26%) | 44 (66%) |
Gleason score | |||
 6–7 | 70 (54%) | 44 (71%) | 26 (39%) |
 8–9 | 59 (46%) | 18 (29%) | 41 (61%) |
Median PSA at RPE | 10.85 (2.37–190) | 8.55 (2.37–48) | 18.05 (3.99–190) |
Postoperative PSA | 0.12 (< 0.03–40.13) | < 0.03 | 0.47 (0.08–40.13) |
Months since RPE | 33 (2–192) | 61 (9–192) | 8 (2–94) |
Median PSA at PSMA PET/CT | 0.62 (0.13–40.13) | 0.44 (0.15–6.24) | 0.90 (0.13–40.13) |
Median PSA at PSMA PET/CT in PET positive pts | 1.09 (0.14–40.13) | 0.78 (0.27–6.24) | 1.6 (0.14–40.13) |
Median PSA at PSMA PET/CT in PET negative pts | 0.3 (0.13–3.24) | 0.3 (0.13–3.24) | 0.34 (0.13–1.33) |
PSMA PET/CT result | |||
 Negative | 51 (39%) | 31 (50%) | 20 (30%) |
 Fossa recurrence only | 24 (19%) | 16 (26%) | 8 (12%) |
 Lymph node positive only | 42 (33%) | 12 (19%) | 30 (45%) |
 Fossa and lymph node recurrence | 12 (9%) | 3 (5%) | 9 (13%) |